Ademi LLP is investigating Bio-Techne's $11.3 billion sale to Merck for possible breaches of fiduciary duty by the board and unfair deal terms. Shareholders will get $73 per share, but insiders may gain extra benefits. The deal restricts competing bids with heavy penalties, raising concerns about shareholder rights. The investigation aims to ensure the board acted in all shareholders' best interests during the transaction.

More News (TECH)

Germany's Merck to buy Bio-Techne for $11.3 billion, shares jump pre-market

Germany's Merck KGaA has agreed to acquire Bio-Techne for $11.3 billion, causing Bio-Techne shares to surge before the market opened. This acquisition highlights Merck's strategic expansion in the biotech sector. The deal is significant for investors...

Company Fundamentals

Bullish

23 hours ago